Cyrus Biotechnology raises $18M and acquires Orthogonal Biologics, adding COVID-19 decoy therapeutic and deep mutational scanning platform

Seattle protein engineering company Cyrus Biotechnology raised $18 million and acquired Orthogonal Biologics, adding a deep mutational scanning platform and two protein therapeutics including a potential COVID-19 decoy. Cyrus leverages University of Washington IPD tools (Rosetta, RoseTTAfold) and has partnerships including a deal with Selecta Biosciences worth up to $1.5 billion.

CCyrus Biotechnology UUniversity of Washington